BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 36134017)

  • 1. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
    Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
    Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse Gliomas with
    Marastoni E; Mulone D; Barresi V
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730596
    [No Abstract]   [Full Text] [Related]  

  • 3. RNAi technology targeting the
    Parker Kerrigan BC; Ledbetter D; Kronowitz M; Phillips L; Gumin J; Hossain A; Yang J; Mendt M; Singh S; Cogdell D; Ene C; Shpall E; Lang FF
    Neurooncol Adv; 2020; 2(1):vdaa132. PubMed ID: 33241214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
    Picca A; Di Stefano AL; Savatovsky J; Ducray F; Chinot O; Moyal EC; Augereau P; Le Rhun E; Schmitt Y; Rousseaux N; Yepnang AMM; Estellat C; Charbonneau F; Letourneur Q; Branger DF; Meyronet D; Fardeau C; Mokhtari K; Bielle F; Iavarone A; Sanson M
    Neurooncol Adv; 2024; 6(1):vdae068. PubMed ID: 38813112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition.
    Barsouk A; Elghawy O; Stone S; Singh A
    Anticancer Drugs; 2024 Apr; ():. PubMed ID: 38696710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retraction Notice to: Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
    Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C
    Mol Ther; 2024 May; ():. PubMed ID: 38701794
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience.
    Ji MS; Eldred BSC; Liu R; Pianka ST; Molaie D; Kevan B; Pan S; Lai TJ; Nguyen NT; Chow FE; Yong WH; Cox CD; Reeh DN; Li T; Liau LM; Nghiemphu PL; Cloughesy TF; Li G; Lai A
    Neurooncol Adv; 2020; 2(1):vdaa009. PubMed ID: 32118206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RT-PCR assay to detect
    Priesterbach-Ackley LP; van Kuik J; Tops BBJ; Lasorella A; Iavarone A; van Hecke W; Robe PA; Wesseling P; de Leng WWJ
    Neurooncol Pract; 2024 Apr; 11(2):142-149. PubMed ID: 38496910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
    Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Metastasis of Pediatric Diffuse High-grade Astrocytoma: A Case Report.
    Chiba K; Aihara Y; Oda Y; Masui K; Komori T; Yokoo H; Kawamata T
    NMC Case Rep J; 2023; 10():265-271. PubMed ID: 37953909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and Molecular Characteristics of
    Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL
    Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
    Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
    Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioblastoma,
    Broggi G; Piombino E; Altieri R; Romano C; Certo F; Barbagallo GMV; Vigneri P; Condorelli D; Colarossi L; Colarossi C; Magro G; Tirrò E
    Front Neurol; 2022; 13():823015. PubMed ID: 35222252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
    Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
    Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
    Gött H; Uhl E
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extra-CNS and dural metastases in
    Kleinschmidt-DeMasters BK; Gilani A
    Neurooncol Pract; 2022 Oct; 9(5):449-455. PubMed ID: 36134017
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.